EULAR 2021
Early detection of PsA & patient stratification
high5immunology.tv | Rheumatology | EULAR 2021
EULAR 2021
Early detection of PsA & patient stratification
EULAR 2021
Update GRAPPA recommendations & axial PsA vs axSpA
EULAR 2021
Treatment decissions and therapeutic options in PsA
EULAR 2021
RA treatment - status and perspectives
EULAR 2021
Early detection and treatment of RA
EULAR 2021
Difficult to treat RA - hot topics and challenges
EULAR 2021
Switching of treatment from reference etanercept to…
EULAR 2021
JAKi in real life!
EULAR 2021
Vitamin D level in response to biologics
EULAR 2021
RA activity and risk of complications after…
EULAR 2021
Recurrence of joint inflammation
EULAR 2021
Using anti-TNF to deliver corticosteroids to…
EULAR 2021
Clinical outcome after switching between IL-6 and JAK…
EULAR 2021
Interstitial lung disease in patients with RA
EULAR 2021
Risk of cardiovascular events and disease activity
EULAR 2021
Influence of comorbitidy on mortality
EULAR 2021
Passive smoking in childhood and adulthood increases…
EULAR 2021
Definition of difficult to treat rheumatoid arthritis
EULAR 2021
JAKi dans la vraie vie!
EULAR 2021
Vitamine D et réponse aux biomédicaments
EULAR 2021
Complications après arthroplastie selon l’activité du…
EULAR 2021
Où les arthrites récidivent-elles?
EULAR 2021
Interstitiell lungesykdom hos pasienter med RA
EULAR 2021
Risiko for kardiovaskulære hendelser og…
EULAR 2021
Påvirkning av komorbiditeter på mortalitet
EULAR 2021
El tabaquismo pasivo aumenta el riesgo de padecer una…
EULAR 2021
Definición de artritis reumatoide difícil de tratar
EULAR 2021
Cardiovascular risk and metabolomic profiling in PsA
EULAR 2021
Deucravacitinib (TYK2 Inhibitor) in Psoriasis and…
EULAR 2021
Secukinumab: Adherence in PsA and AS
EULAR 2021
Hyperuricemia: increased risk of severe PsA course
EULAR 2021
Power-Doppler ultrasound of the achilles tendon to…
EULAR 2021
GRAPPA Recommendations 2021
EULAR 2021
Faeceal microbiota transplantation
EULAR 2021
Role of Sex and Weight on PsA
EULAR 2021
Kardiovaskuläres Risiko und metabolomisches Profil bei…
EULAR 2021
Deucravacitinib (TYK 2 Inhibitor) neu bei PsA und…
EULAR 2021
Secukinumab: Adhärenz bei PsA and AS
EULAR 2021
Cave Hyperurikämie: Erhöhtes Risiko für schweren…
EULAR 2021
Power-Doppler-Sono AS: Differenzierung Belastung vs.…
EULAR 2021
GRAPPA Empfehlungen 2021
EULAR 2021
Rolle von Geschlecht und Gewicht
EULAR 2021
Do patients with axSpA help us?
EULAR 2021
Feasibilty of anti-TNF tapering in low disease…
EULAR 2021
Non-radiographic or radiographic axial SpA - does it…
EULAR 2021
Radiographic progression in axSpA
EULAR 2021
Impact of sex on BASDAI scores
EULAR 2021
¿Nos ayudan los pacientes con espondiloartritis axial?
EULAR 2021
Impatto del sesso sugli score del BASDAI
EULAR 2021
Progresión radiográfica en espondiloartritis axial
EULAR 2021
fattibilità della riduzione del dosaggio degli anti-TNF…
EULAR 2021
COVID-19 outcome in inflammatory arthropathy patients
EULAR 2021
Rituximab and COVID-19 (Nat. French Registry Study)
EULAR 2021
Outcome of Covid-19 in Rheumatoid Arthritis under…
EULAR 2021
COVID-19 Vaccination in patients with rheumatic disease
EULAR 2021
Influence of TNF-Inhibition on COVID-19
EULAR 2021
Risk factors of COVID-19 course in SLE
EULAR 2021
Rituximab and COVID-19 (Multicenter-Study)
EULAR 2021
Immunogenicity of mRNA-COVID-19 vaccine in patients…
EULAR 2021
Rituximab bei COVID-19 (franz. Registerdaten)
EULAR 2021
Rituximab bei COVID-19 (Multicenter-Studien)
EULAR 2021
Immunogenicidad de la vacuna mRNA-COVID-19 en pacientes…
EULAR 2021
COVID-19 bei SLE
EULAR 2021
Einfluss von TNF-Blockern auf COVID-19-Verlauf
EULAR 2021
Patientenumfrage während der Pandemie
EULAR
SARS-CoV2-Impfung bei Rheumapatienten
EULAR 2021
Combination of Belimumab and Rituximab is beneficial
EULAR 2021
Convincing Anifrolumab data on efficacy and drug…
EULAR 2021
New therapy for cutaneous manifestations
EULAR 2021
Kombination Belimumab und Retuximab vorteilhaft
EULAR 2021
Anifrolumab in Wirksamkeit und Verträglichkeit…
EULAR 2021
Neue Therapie für kutane Manifestationen
EULAR 2021
What is new in Giant Cell Arteritis?
EULAR 2021
Tocilizumab Monotherapy for Giant Cell Arteritis - the…
EULAR 2021
Ultrasound halo sign as a potential monitoring tool for…
EULAR 2021
Efficcacy and Safety of TNF-α Blockers and Tocilizumab…
EULAR 2021
Efficacia e sicurezza degli anti-TNF e del tocilizumab…
EULAR 2021
Monoterapia con tocilizumab nella arterite a cellule…
EULAR 2021
Lung involvement: diagnostic work-up and new treatment…
EULAR 2021
Fatigue in Arthritis, SpA & systemic rheumatic diseases
EULAR 2021
Risk factors for ADAb formation: Data from the NOR-DRUM…
EULAR 2021
Lyme disease: Myths and reality
EULAR 2021
Secukinumab in patients with rotator cuff tendinopathy
EULAR 2021
Therapeutic drug monitoring and immunogenicity
EULAR 2021
Factores de riesgo del desarrollo de anticuerpos…
EULAR 2021
EULAR, najnowsze postępy w reumatologii
EULAR 2021
Co nowego w reumatologii dziecięcej
EULAR 2021
Therapeutic drug monitoring (TDM) og immunogenisitet
Für den erfolgreichen Abschluss der Fortbildungsmodule ist die korrekte (mind. 70%) Beantwortung der Lernerfolgskontrolle für das jeweilige Modul verpflichtend.
Jetzt gleich den Fragebogen ausfüllen!